Comments
Loading...

Atea Pharmaceuticals

AVIRNASDAQ
Logo brought to you by Benzinga Data
$2.93
-0.02-0.68%
At close: -
$2.93
0.000.00%
After Hours: 4:00 PM EDT
Consensus Rating1
Equal-Weight
Highest Price Target1
$6.88
Lowest Price Target1
$6.00
Consensus Price Target1
$6.44

Atea Pharmaceuticals (NASDAQ:AVIR) Stock, Analyst Ratings, Price Targets, Forecasts

Atea Pharmaceuticals Inc has a consensus price target of $6.44 based on the ratings of 3 analysts. The high is $6.88 issued by Morgan Stanley on August 13, 2024. The low is $6 issued by SVB Leerink on January 27, 2023. The 3 most-recent analyst ratings were released by Morgan Stanley, JP Morgan, and SVB Leerink on August 13, 2024, March 16, 2023, and January 27, 2023, respectively. With an average price target of $6.96 between Morgan Stanley, JP Morgan, and SVB Leerink, there's an implied 137.54% upside for Atea Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Aug
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Morgan Stanley
SVB Leerink

1calculated from analyst ratings

Analyst Ratings for Atea Pharmaceuticals

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Atea Pharmaceuticals (AVIR) stock?

A

The latest price target for Atea Pharmaceuticals (NASDAQ:AVIR) was reported by Morgan Stanley on August 13, 2024. The analyst firm set a price target for $6.88 expecting AVIR to rise to within 12 months (a possible 134.81% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?

A

The latest analyst rating for Atea Pharmaceuticals (NASDAQ:AVIR) was provided by Morgan Stanley, and Atea Pharmaceuticals upgraded their equal-weight rating.

Q

When was the last upgrade for Atea Pharmaceuticals (AVIR)?

A

The last upgrade for Atea Pharmaceuticals Inc happened on August 13, 2024 when Morgan Stanley raised their price target to $6.88. Morgan Stanley previously had an underweight for Atea Pharmaceuticals Inc.

Q

When was the last downgrade for Atea Pharmaceuticals (AVIR)?

A

The last downgrade for Atea Pharmaceuticals Inc happened on August 10, 2023 when JP Morgan changed their price target from N/A to N/A for Atea Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on August 13, 2024 so you should expect the next rating to be made available sometime around August 13, 2025.

Q

Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?

A

While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a upgraded with a price target of $2.00 to $6.88. The current price Atea Pharmaceuticals (AVIR) is trading at is $2.93, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch